Knight Therapeutics Company Profile (CVE:GUD)

About Knight Therapeutics (CVE:GUD)

Knight Therapeutics logoKnight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company's product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: CVE:GUD
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: C$1.42 billion
  • Outstanding Shares: 142,720,000
Average Prices:
  • 50 Day Moving Avg: C$10.34
  • 200 Day Moving Avg: C$10.26
  • 52 Week Range: C$7.88 - C$11.03
  • Trailing P/E Ratio: 55.84
  • P/E Growth: 2251.00
Sales & Book Value:
  • Annual Revenue: C$6.62 million
  • Price / Sales: 214.30
  • Book Value: C$6.89 per share
  • Price / Book: 1.44
  • EBIDTA: ($7,530,000.00)
  • Average Volume: 142,816 shs.
  • Short Ratio: 4.64

Frequently Asked Questions for Knight Therapeutics (CVE:GUD)

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GUD."

Who are some of Knight Therapeutics' key competitors?

How do I buy Knight Therapeutics stock?

Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Knight Therapeutics stock cost?

One share of Knight Therapeutics stock can currently be purchased for approximately C$9.94.

Analyst Ratings

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
No equities research coverage for this company has been tracked by


Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by


Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.15 EPS


Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by


Headline Trends for Knight Therapeutics (CVE:GUD)
Latest Headlines for Knight Therapeutics (CVE:GUD)
DateHeadline logoCan Knight Therapeutics Inc. Repeat the Success of Paladin Labs? - The Motley Fool Canada - May 19 at 10:06 AM logoBRIEF-Knight therapeutics Q1 EPS $0.04 - May 12 at 11:15 PM logoEdited Transcript of GUD.TO earnings conference call or presentation 11-May-17 12:30pm GMT - May 11 at 11:10 PM logoKnight Therapeutics' (KHTRF) Management on Q1 2017 Results - Earnings Call Transcript - May 11 at 6:09 PM logoSynergy CHC Corp. Announces Private Placement Offering of up to US$20 Million - May 3 at 3:03 PM logoKnight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto - April 25 at 11:00 AM logoKnight Therapeutics Announces the Canadian commercialization of MOVANTIK® - March 13 at 11:10 AM logoKnight Therapeutics Inc. Announces Board Change - Benzinga - February 23 at 5:33 PM logoKnight Therapeutics Acquires 6.2M Shares of Protalix BioTherapeutics (PLX) - January 27 at 7:29 PM logoKnight Plants Small Seed Position In Protalix - January 27 at 12:04 AM logoKnight Disposes of Shares of Pediapharm Inc. - January 13 at 11:46 PM logoAPI Is Core to Knight's Successful Investment - January 9 at 4:27 PM logoMedicure Provides Apicore Secured Loan to Replace Knight Loan - January 9 at 4:27 PM logoThe Top 5 Buys of Canada's CI Can-Am Small Cap Fund - December 16 at 11:08 PM logoExclusive: Endo International considers sale of Paladin Labs to Knight Therapeutics: sources - November 4 at 4:17 PM logoIf $10,000 fell into your lap, what would you do? - September 1 at 8:16 AM logoKnight Medison Relationship Continues to Pay Dividends - August 15 at 10:16 AM logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX - August 2 at 5:37 PM logoKNIGHT THERAPEUTICS INC - May 26 at 12:31 PM logo3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into Advisory Agreement With Knight Therapeutics Inc. - May 26 at 12:16 PM logoKnight Reports First Quarter 2016 Results - May 10 at 6:00 AM logoKnight Blooms at Healthcare Investor Conference in Toronto - April 25 at 8:00 AM logoKnight Receives NOD from Health Canada for ATryn(R) - April 25 at 8:00 AM logoKnight Finds EMPAthetic Partner for Neuragen(R) in the Middle East - April 25 at 8:00 AM logoQ4 2015 KNIGHT THERAPEUTICS Inc Earnings Release - Time Not Supplied - March 24 at 7:07 AM logoKnight Reports Fourth Quarter and Year-Ended December 31, 2015 Results - March 24 at 6:00 AM logoKnight Receives Dividend From Medison - March 23 at 8:00 AM logoKnight Partner Profounda Inc. Launches Impavido in U.S. - March 22 at 8:03 AM logoProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States - March 22 at 7:59 AM logoKnight Obtains Impavido Worldwide Rights - March 15 at 8:00 AM logoKnight Therapeutics Inc. (GUD.TO) - January 16 at 2:29 PM logoCRH Makes GUD on Knight Secured Loan - November 25 at 8:00 AM logoKnight to Present at the TD Securities Technology & Healthcare Conference in Toronto - November 17 at 8:00 AM logoKnight Partner FOCUSed on Growth - November 16 at 8:00 AM logoKnight Supports Operation Antibe - November 16 at 8:00 AM logoKnight Reports Third Quarter Financial 2015 Results - November 11 at 6:00 AM logoThe Knight Medison Relationship Already Paying Dividends - November 2 at 8:00 AM logoKnight Profounda U.S. Partner for Impavido - September 28 at 8:00 AM



Knight Therapeutics (GUD) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff